Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic

Nassim Kamar; Laure Esposito; Anne L Hebral; Joelle Guitard; Arnaud Del Bello

doi:10.1111/ajt.16074

Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic

Am J Transplant. 2020 Oct;20(10):2962-2963. doi: 10.1111/ajt.16074. Epub 2020 Jul 15.

Authors

Nassim Kamar^{1

2

3}, Laure Esposito¹, Anne L Hebral¹, Joelle Guitard¹, Arnaud Del Bello^{1

2}

Affiliations

¹ Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
² INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.
³ Université Paul Sabatier, Toulouse, France.

No abstract available

Keywords: clinical research/practice; complication: infectious; immunosuppressant-fusion proteins and monoclonal antibodies: belatacept; immunosuppression/immune modulation; infectious disease.

Publication types

Letter

MeSH terms

Abatacept / administration & dosage*
Betacoronavirus*
COVID-19
Coronavirus Infections / epidemiology
Coronavirus Infections / transmission*
Cross Infection / prevention & control*
Graft Rejection / etiology
Graft Rejection / prevention & control*
Graft Survival
Humans
Immunosuppressive Agents / administration & dosage
Infusions, Intravenous
Kidney Transplantation*
Pandemics*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / transmission*
SARS-CoV-2

Substances

Immunosuppressive Agents
Abatacept